Purpose: CXCR4 is overexpressed on tumor cells from many types of human cancers. A high level of CXCR4 expression often correlates with poor prognosis, chemotherapy resistance, and metastasis. The development of CXCR4-specific radiotracers for positron emission tomography (PET) imaging will allow in vivo evaluation of receptor expression level for diagnosis or therapeutic evaluation. 18 F]FP-Ac-TC14012 showed higher tumor uptake and better tumor-to-background contrast. Unlike their N-terminal 4-F-benzoate analogs, these two tracers had minimal blood retention, likely due to reduced red blood cell binding. Metabolic organs, such as the liver and kidney, also showed high uptake. When blocked with low-dose cold peptide (10 μg), the tumor uptake was significantly increased, most likely due to the increased concentration in blood circulation, as evidenced by decreased liver uptake.
Introduction
C hemokine receptors are cytokine receptors found on the surface of certain cells that interact with a chemokine. There have been 19 distinct chemokine receptors described in mammalian cells. Each chemokine receptor has a seventransmembrane structure and couples to G protein for signal transduction within a cell. CXCR4, belonging to the family of CXC chemokine receptors, is overexpressed on tumor cells from at least 23 different types of human cancers, including epithelial, mesenchymal, and hematopoietic origins [1] . CXCL12 (or SDF1-α) is the only known natural ligand for CXCR4.
CXCR4 is found in primary tumor sites in lymphoma, glioma, ovarian, and pancreatic cancers [2] [3] [4] [5] and at the sites of metastasis in breast, lung, thyroid, neuroblastoma, hematological cancers, and inflammatory diseases [6] [7] [8] [9] [10] . It is also constitutively expressed in many normal organs, including the spleen, pancreas, and bone marrow [11, 12] . Research on the role of CXCR4 in cancer has revealed a correlation between high level of CXCR4 expression and poor prognosis [13, 14] , chemotherapy resistance [15] [16] [17] , and metastasis [18, 19] in CXCL12-expressing organs. Therefore, the CXCR4 ligand or antagonist could be an effective strategy for both therapeutic and imaging purposes. Indeed, Plerixafor (AMD3100, a small molecular CXCR4 antagonist) has been used in the clinic as an immunostimulant to mobilize hematopoietic stem cells for transplantation.
Development of CXCR4-specific radiotracers for positron emission tomography (PET) imaging will allow in vivo evaluation of receptor expression level for diagnostic or therapeutic evaluation. A few CXCR4 ligands have been radiolabeled for PET imaging, including small molecules [20] [21] [22] [23] and peptides [24] [25] [26] [27] [28] [29] , although an optimal imaging agent is still yet to be found. The extensive research by Tamamura and coworkers has led to the finding and optimization of a 14-amino-acid CXCR4 inhibitor T140 peptide and its derivatives [30] [31] [32] [33] . Previously in our group, a TN14003 peptide [33] has been labeled with 4-[
18 F]-fluorobenzoate at the N terminus for CXCR4 imaging in vivo [25] . Although this radiotracer possesses excellent CXCR4 binding affinity, it shows very high red blood cell (RBC) binding as well. The RBC binding resulted in low tumor-to-background contrast in vivo. Also, the side chains of Lys 7 and Lys 8 need to be protected before labeling, which adds a deprotection step. When labeled with 64 Cu through chelators at the side chains of Lys 7 and Lys 8 while keeping the N-fluorobenzoate group [26] , the high CXCR4 binding affinity remains but the high RBC binding is still similar. Furthermore, when 64 Cu-labeling is done at the N terminus [27] , although the binding affinity was decreased by 1-2 orders of magnitude, the RBC binding is greatly diminished, which provides a better imaging contrast in vivo. In this manuscript, we developed two new 18 F-labeled radiotracers based on an Ac-TC14012 peptide (Fig. 1) . The Ac-TC14012 peptide has shown very low EC 50 (29 nM) in anti-HIV activity [33] . There is only one Lys 7 ε-amine group in the peptide sequence for labeling, which could avoid the labeling at multiple sites. Moreover, labeling at the Lys 7 position should not affect its CXCR4 affinity significantly, as it is not essential for CXCR4 binding [30, 33] . Also, labeling at the Lys 7 side chain results in very low RBC binding without reducing CXCR4 binding affinity significantly, comparing to Nterminal 4-F-fluorobenzoate-conjugated analogs [25, 26] . Their behaviors for in vivo PET imaging of CXCR4 were evaluated and discussed.
Materials and Methods
All solvents and chemicals were purchased from Sigma-Aldrich (St. Louis, MO, USA) or Fisher Scientific (Waltham, MA, USA) and used as received. Ac-TC14012 (sequence Ac-Arg-Arg-NaICys-Tyr-Cit-Lys-DCit-Pro-Tyr-Arg-Cit-Cys-Arg-NH 2 Cys4-Cys13 disulfide) was purchased from C.S. Bio Co. (Menlo Park, CA, USA). Mass spectra were obtained with a Waters LC-MS system (Waters, Milford, MA, USA) that included an Acquity UPLC system coupled to a Waters Q-Tof Premier high-resolution mass spectrometer.
High-performance liquid chromatography (HPLC) was performed on a system with a variable wavelength detector and with a radioactivity detector containing a NaI crystal. Analytical HPLC used a Phenomenex Luna 5 μm C18 column (5 μm, 4.60× 150 mm). Elution, at 1 ml/min, used a gradient system, starting from 95 % of solvent A (0.1 % trifluoroacetic acid [TFA] in water) and 5 % of solvent B (0.1 % TFA in acetonitrile) and changing to 50 % solvent A and 50 % solvent B at 30 min. The semipreparative HPLC system used a Phenomenex Luna 5 μm C18 column (5 μm, 10×250 mm). The flow was set at 5 ml/min using a gradient system, starting from 95 % of solvent A (0.1 % TFA in water) and 5 % of solvent B (0.1 % TFA in acetonitrile) for 5 min and changing to 35 % solvent A and 65 % solvent B at 35 min.
C18 cartridges (Waters Corporation, Milford, MA, USA) were each activated with 5 ml of EtOH and 10 ml of water. After trapping, the cartridges were washed with 5 ml H 2 O before the desired products were eluted out using 10 mM HCl in ethanol.
Synthesis of 2-Fluoropropionate-Ac-TC14012 (FP-Ac-TC14012)
Three milligrams of Ac-TC14012 peptide was dissolved in 400 μl of dimethyl sulfoxide (DMSO). 4-Nitrophenyl 2-fluoropropionate (1.1 eq) and 5 μl of diisopropylethylamine was added and reacted at room temperature (RT) for 20 min. The reaction was quenched with 10 μl TFA and loaded on semipreparative HPLC (Beckman, Brea, CA, USA; Ultrasphere™ C18 column, 5 μm, 10×250 mm). The desired product was collected at 27 min and lyophilized to afford a white powder with a yield of 56 %. HRMS Calcd for C 95 The activity trapped on the C18 cartridge as described previously was eluted manually with 1 ml of methylene chloride into a 1.5-ml polypropylene tube, and the water layer on top of the methylene chloride was removed by using a syringe. The methylene chloride in the tube was evaporated under argon flow at RT, and 200 μg of Ac-TC14012 in 0.1 ml of DMSO containing 5 μl of diisopropylethylamine was added to the tube and heated at 80°C for 10 min. At the end of the reaction, the reaction mixture was cooled and diluted with 0.5 ml of water containing 0.1 % of TFA and loaded onto a semi-preparative HPLC column. The desired product was collected at a retention time of 18.9 min and diluted with 10 ml water and trapped on a Varian Bond Elute C18 column (100 mg). The radioactivity trapped on the C18 column was eluted with 0.15 ml of 10 mM HCl-ethanol solution, the ethanol was removed with argon flow, and the final product was then dissolved in phosphate-buffered saline (PBS). In a typical experiment, 2.4 mCi of product could be obtained starting from 9.4 mCi of [
18 F]-FP with a total synthesis time of~50 min. The radiochemical yield for coupling of [
18 F]FP with Ac-TC14012 was 38.1±10.5 % (mean±SD, n04, decay corrected). The quality control on an analytical HPLC showed t R 017.5 min and radiochemical purities≥95 %. 
Synthesis of N-succinimidyl

F]FB-Ac-TC14012
The activity trapped on the C18 cartridge as described previously was eluted manually with 1 ml of methylene chloride into a 1.5-ml polypropylene tube, and the water layer on top of the methylene chloride was removed by using a syringe. The methylene chloride in the tube was evaporated under argon flow at RT, and 200 μg of Ac-TC14012 in 0.1 ml of 100 mM pH 8.5 Na 2 HPO 4 buffer was added to the tube and reacted at RT for 20 min. At the end of the reaction, the reaction mixture was diluted with 0.5 ml of water containing 0.1 % of TFA and loaded onto a semi-preparative HPLC column. The desired product was collected at a retention time of 20.5 min and diluted with 10 ml water and trapped on a Varian Bond Elute C18 column (100 mg). The radioactivity trapped on the C18 column was eluted with 0.15 ml of 10 mM HCl-ethanol solution. The ethanol was removed with argon flow, and the final product was then dissolved in PBS. In a typical experiment, 2.0 mCi of product could be obtained starting from 10.7 mCi of [
18 F]-FB with a total synthesis time of 60 min. The radiochemical yield for coupling of [ 18 F]-FB with Ac-TC14012 was 31.6±7.0 % (mean±SD, n04, decay corrected). The quality control on an analytical HPLC showed t R 019.5 min and radiochemical purities≥98 %.
Cell Culture and Flow Cytometry
Wild-type Chinese hamster ovarian (CHO) cells and CHO cells that were stably transfected with CXCR4 (CHO-CXCR4) were a kind gift from Dr. David McDermott (NIAID, NIH, Bethesda, MD, USA). The cells were cultured following a previously reported procedure [25] . The CXCR4 expression level was confirmed by flow cytometry by using PE-conjugated antihuman CXCR4 (R&D, Minneapolis, MN, USA) and an LSR-II cytometer (Becton Dickinson, San Jose, CA, USA). The flow data were analyzed using FlowJo (Tree Star, Ashland, OR, USA). 125 I]CXCL12, and 0-1,000 nM of Ac-TC14012, FP-Ac-TC14012, or FB-Ac-TC14012 peptide for 45 min on a shaker at RT, respectively. The cell-bound radioactivity was measured using a gamma counter and expressed as percent of total counts. The IC 50 values were calculated using Prism software (GraphPad, La Jolla, CA, USA).
Competitive Binding Assay
Cell Uptake and Efflux Studies
For cell uptake studies, CHO-CXCR4 or CHO cells were seeded into a 24-well plate (10 5 cells per well) and incubated with 18 F-labeled TC14012 derivatives (25 μCi/well, 925 kBq/ well) at 37°C. Cells were then washed twice with cold PBS at different time points and harvested by addition of 250 μl of 0.1 M NaOH. Internalization studies were conducted in a similar fashion. After incubation of CHO-CXCR4 cells with radiotracers at 37°C for different amounts of time, the cells were washed twice with cold PBS and then incubated with acid washing buffer (50 mM glycine, 0.1 M NaCl, pH 2.8) for 1 min to remove surface-bound radioligand. Thereafter, the cells were further washed with cold PBS and harvested by adding 250 μl of 0.1 M NaOH. For efflux studies, radiotracers (25 μCi/well, 925 KBq/well) were added to the cells in a 24-well plate and incubated for 60 min at 37°C. Then, the cells were washed with cold PBS and incubated with F-12K medium for different amounts of time. After washing twice with PBS, cells were harvested by addition of 250 μl of 0.1 M NaOH. The collected radioactivity from each well was measured in a gamma counter. Each data point is an average of triplicate wells.
Animals
All animal studies were conducted in accordance with the principles and procedures outlined in the National Institutes of Health Guide for the Care and Use of Animals using protocols approved by the NIH Institutional Animal Care and Use Committee. Athymic nude mice (4-6 weeks old from Taconic, Germantown, NY, USA) were injected subcutaneously at two sites on the shoulder with 10 7 CXCR4-positive or CXCR4-negative CHO tumor cells per site. The imaging or biodistribution studies were performed 2 weeks after tumor inoculation.
PET Studies
For PET scans, each mouse was injected via the tail vein with 100 μCi (3.7 MBq) of radiotracers in a volume of 100 μl PBS under isoflurane anesthesia. The images were acquired using an Inveon scanner (Siemens Medical Solutions) at 0.5 and 1 h postinjection (p.i.). For blocking experiments, 100 μCi (3.7 MBq) of radiotracers were co-injected with 10, 50, or 200 μg of Ac-TC14012 peptide. The images were reconstructed by a threedimensional ordered subsets expectation maximization algorithm with no attenuation or scattering correction. Image analysis was done using ASI Pro VMTM software. Tumor and tissue uptake values derived from coronal PET images were obtained by analyzing regions of interest and converting the values to percent injected dose per gram tissue (n04-6/group).
Biodistribution
For biodistribution, each animal was injected with the appropriate PET tracer (50 μCi, 1.85 MBq) in 100 μl PBS. For the experiment, 50 μg of Ac-TC14012 peptide were co-injected with the labeled peptide. At 2 h p.i., the animals were sacrificed, tumor and major organs and tissues were collected, wet weighed, and the radioactivity was measured by a gamma counter. The results were calculated as percent injected dose per gram tissue (n04-6/group).
X.
Statistical Analysis
Two-tailed paired and unpaired Student's t tests were used to test differences between groups. Comparisons are made between CHO-CXCR4 and CHO tumors and between unblocked and blocked experiments. P value G0.05 was considered statistically significant.
Results and Discussion
Synthesis and Radiochemistry
Nonradioactive FP-Ac-TC14012 and FB-Ac-TC14012 were synthesized as standards for confirming the identity of radiolabeled compounds and for cell binding assays. [34] . The total synthesis time for [ 18 F]FP was~100 min with uncorrected yield of 12.4±3.4 % (mean±SD, n04). The radiolabeling of Ac-TC14012 with [ 18 F]FP was carried out in DMSO using DIPEA as a base. After reaction at 80°C for 10 min, the labeled peptide was isolated by semi-preparative HPLC. The radiochemical yield of labeling was 38.1± 10.5 % (mean±SD, n04, decay corrected), with radiochemical purities ≥ 95 % (for the HPLC chromatogram, see Supplemental Materials Fig. S1 ). The specific activity ranged from 13.6 to 17.6 GBq/μmol at the time of measurement (prior to animal studies).
The radiosynthesis of N-succinimidyl 4-[ 18 F]-fluorobenzoate ([ 18 F]FB) also utilized three-step procedures and were performed using automated procedures [35] . The total synthesis time for [ 18 F]FB was~110 min with uncorrected yield of 17.4±5.7 % (mean±SD, n04). When labeling with [ 18 F]FB, a preliminary test of reaction buffers was first performed. At pH 8.5 (100 mM sodium bicarbonate, 100 mM sodium phosphate, or 100 mM sodium borate buffer, pH adjusted using 5 M NaOH and HCl), the coupling reaction at RT for 30 min provided similar radiolabeling yields of 59-75 % (calculated from HPLC peak integration), while higher or lower pH (9.20 or 8.20, NaHCO 3 buffer) resulted in significantly lower yields (11-28 %); 100 mM pH 8.5 Na 2 HPO 4 buffer was used thereafter. In radiolabeling, when peptide was in large excess, the two side products seen in nonradioactive synthesis were much less, with labeling yield of desired product 55-65 % (calculated from HPLC peak integration). The radiochemical yield for coupling of [ (Fig. 2a) . The affinities of the FPAconjugated or SFB-conjugated peptides to CXCR4-transfected CHO cells were evaluated in a competitive binding assay with [
125 I]CXCL12 radioligand, which has been widely used for CXCR4 ligand binding affinity measurement since CXCL12 (SDF1-α) is a natural ligand to CXCR4 with high affinity. As shown in Fig. 2b , the IC 50 of the unconjugated Ac-TC14012 peptide was found to be 2.47±0.53 nM (mean±SD), while the IC 50 s of FP-Ac-TC14012 and FB-Ac-TC14012 were 7.52±1.62 and 25.1± 5.3 nM, respectively. These IC 50 values are lower compared to N-terminal chelator-conjugated TN14003 peptides [27] , demonstrating the minor role of Lys 7 in receptor binding. Also, the larger and more hydrophobic FB group has a larger effect on the binding affinity than the FP group.
Cell Uptake and Retention
The cell uptake and retention of [ (Fig. 3c) ; the retention after 1 h was 37.38±0.77 and 18.76± 0.26 % for CHO-CXCR4 and CHO cells, respectively (Fig. 3d) . Eighty-one percent of the uptaken dose was retained in CHO-CXCR4 cells, and 68 % was retained in CHO cells. 
PET Imaging
In vivo imaging of CXCR4 expression was evaluated by static microPET scan using mice bearing subcutaneous CHO-CXCR4 and CHO tumors. The radiotracers were injected intravenously and the representative decay-corrected coronal images at 30 and 60 min after injection of the radiotracers are shown in Figs. 4 and 5 . The CHO-CXCR4 tumors were clearly visualized with good tumor-to-background contrast with both tracers at 30 min p.i., while the CHO tumors, with low CXCR4 expression, showed much lower uptake. Unlike previously reported N-fluorobenzoate TN140003 peptides [25, 26] , these radiotracers showed much less blood retention, likely due to 65±0.14 %ID/g; PG0.01 compared to co-injection with 10 μg cold peptide); and the uptake was not significantly different than the CXCR4-negative CHO tumor (P90.05). The co-injection of unlabeled peptide also resulted in decreased liver uptake and increased kidney uptake, indicating that the liver may have specific uptake and the kidney is a major metabolism and/or excretion organ. . At blocking doses of 50 μg cold peptide (~50-fold excess), CHO-CXCR4 tumor uptake decreased; the uptake was not significantly different between CHO-CXCR4 and CHO tumors (P90.05) for both radiotracers. Although the uptake in CXCR4-negative CHO tumors also increased, the change was not significant (P90.05).
For the N-terminal 4-F-benzoate analogs [25, 26] , the radiotracers showed very high blood retentions (12-15 %ID/ g). In comparison, the radiotracers reported here only showed 0.7 and 0.8 %ID/g in the blood for [ 18 F]FP-labeled and [
18 F]FB-labeled peptides, respectively. These results ]FB-Ac-TC14012, respectively), which is a CXCR4-expressing organ. This specific uptake was blocked by co-injection of unlabeled peptide in approximately the same proportion (50 %) as observed in the CXCR4-transfected tumor. In addition to the spleen, high uptake in the liver and kidney was similar as previously observed for other T140-based imaging agents [26, 27, 29, 39] . For both radiotracers, after co-injection with nonradioactive peptide, the liver uptake decreased significantly, implying some proportion of specific uptake, as it was reported that mouse liver expresses high levels of CXCR4 messenger RNA [40] . Meanwhile, the kidney uptake increased as the blocking dose increased, consistent with the microPET imaging results. The uptake in the blood, muscle, and all other major organs were very low and not affected by the co-injection of unlabeled peptide.
Several T140 peptide derivatives have been labeled by different methods for SPECT or PET imaging of CXCR4. Each derivative has its own advantages and disadvantages. For example, labeling of an Ac-TZ14011 peptide with [ 111 In]DTPA resulted in only 0.51 %ID/g uptake in a pancreatic AsPC-1 tumor model, despite similar IC 50 values of the labeled and unlabeled peptides [41] . The Nfluorobenzoate TN14003 peptide has very high binding affinity regardless of labeling, but showed high RBC binding in vivo, which resulted in low imaging contrast [25, 26] . The small-molecule CXCR4 antagonists AMD3100/AMD3465 have been labeled with 64 Cu for PET imaging as well [20] [21] [22] [23] . These radiotracers showed similar uptake patterns: high liver and kidney uptake were also observed; the liver uptake can be blocked by cold compounds, while metal transchelation was also present. For the study that used a X.-X. Zhang et al.: Comparison of 18 F-labeled CXCR4 antagonist peptides for PETsimilar animal model, high radiotracer accumulation (12 %ID/g) was seen in CXCR4-positive tumor, but only at 6 h p.i.. The two new radiotracers reported here had high tumor uptake with minimal blood retention, which provided good tumor-to-background contrast. Meanwhile, they showed high uptake in metabolic organs, similar as that seen for other T140 peptide analogs, which may make imaging of the abdominal region problematic.
Conclusions
In this manuscript, Ac-TC14012 was labeled with two different 18 . The radiochemical yields were reasonable and radiolabeled products were obtained in high radiochemical purity. When imaging athymic nude mice bearing CHO-CXCR4 and CHO tumors, the CHO-CXCR4 tumors were clearly visualized with good tumor-to-background contrast for both radiotracers, while the uptake in CXCR4-negative CHO tumor was much lower. Co-injection with low dose (10 μg) of unlabeled peptide can further increase the uptake in the CHO-CXCR4 tumor, probably through the blocking of liver uptake. The CHO-CXCR4 tumor uptake can be blocked by higher blocking doses (50 and 200 μg). Among the two radiotracers, the [ 18 F]FP-labeled peptide showed higher tumor uptake, lower nonspecific binding, and better tumor-to-background contrast, which suggests that the smaller size and lower hydrophobicity of the prosthetic group improves in vivo imaging. The work in this manuscript showed the potential of using [ 18 F]FP-Ac-TC14012 for in vivo PET imaging of CXCR4 expression.
